Ethical Issues in Translational Research – Paradigm or Policy Shift?

The First Indiana CTSI Symposium on Disease and Therapeutic Modeling

Eric M. Meslin, Ph.D. Director, IU Center for Bioethics Associate Dean (Bioethics), IU School of Medicine Professor of Medicine, Medical and Molecular Genetics, and Philosophy Director, Bioethics and Subject Advocacy Program, Indiana CTSI



The ONLY Ethical Issue: Traversing the "Valley of Death"



Translational Continuum

Paradigm Shifts?

• individual researchers replaced by teams;

• multiple institutions collaborating with international partners;

• blurring the prevailing division of labor between universities and the private sector;

• funders emphasizing impact over knowledge







Research Ethics Paradigm Shifts?

- increasing emphasis on <u>access</u> to trials, especially involving women and children;
- arguments about the <u>scope of permission</u>, especially to broaden consent for biobanking;
- greater involvement of communities in planning studies;
- increased ethical scrutiny about financial and <u>commercial arrangements</u>
- Clinical trials gold standard \rightarrow genetic exceptionalis

Paradigm Shift?





If it were not for the great variability among individuals, medicine might as well be a science and not an art.

— Sir William Osler (1892)



Some Historical Origins of "Personalized" Medicine







Charaka Samhita, 9th C, B.C.E





- Dramatically re-adjust the benefit-risk profile on medicines (increase benefit, minimize harm)
- Improve targeting of therapies (right drug for them)
- Potential to lower out-of-pocket payment for patients



* Lazarou et al, JAMA (1998)

** Peakman & Arlington, Drug Discovery World (2001)



Overcoming the Valley: Differing Paradigms

- Basic/clinical researchers and clinicians each use somewhat different paradigms – they see the world differently
- 2. Ethical foundations of clinical care are not identical to the ethical foundations of research
- Genetic research is different from clinical trials





The Translational Policy Valley of Death



Personalized Medical Research is Assured Through Regulation and Oversight

Figure C-1: Common Rule and Agency-Specific Human Research Protection Regulations





The World of Biobanking



CENTER FOR BIOETHICS

Lost in Translation

- Policy researchers and policy makers do not interact
- policy researchers think about direct applications of their work, they are not always empowered to implement;
- Differing regulatory philosophies by elected officials
- Variable funding mechanisms





The Politics of Science Policy



HAROLD VARMUS

"Until the mid 1980s, when I was in my mid-forties, I paid relatively little attention to the intersection of politics and science. This did not mean I was apolitical. I followed political events closely and had strong largely left-liberal—opinions about them. Nor was I oblivious to the potential for engagement between politics and science....."



Traversing the Translational Policy Valley of Death

- Politicians and scientists should adopt a pragmatic approach to policy
- Use bioethics as an instrument of science policy not a hammer
- Promote better education about science's contribution to public good
- Re-negotiate the social contract between science and society



Ethical Issues in Translational Research – Paradigm or Policy Shift?

BOTH





Financial Support

- The IU Center for Bioethics Program in Predictive Health Ethics Research (PredictER) is supported by a grant from the Richard M. Fairbanks Foundation, Indianapolis.
- Grant #UL1RR025761-01; NCRR/NIH: Indiana Clinical and Translational Sciences Institute.







410 West 10th Street, Suite 3100 Indianapolis, Indiana USA 46202-3002 Tel: (317) 278-4034 Fax: (317) 278-4050 www.bioethics.iu.edu